# Indraprastha Medical Corporation share price today (Indraprastha Medical Corporation Ltd, NSE: INDRAMEDCO)

> Indraprastha Medical Corporation share price today: ₹336.30 at the NSE close on 4 November 2026, down 45.7% in a year. Indraprastha Medical Corporation (NSE: INDRAMEDCO) is worth ₹3,079 crore, trades at a P/E of 16.1 and has closed between ₹299.80 and ₹619.90 over the past 52 weeks. > Indraprastha Medical Corporation Ltd's earnings have grown faster than its share price. Earnings per share grew +14.1% in a year while the price moved −45.7%. INDRAMEDCO · Hospitals · data as of 4 November 2026. Page: https://www.sectoralpha.in/stocks/indraprastha-medical-corporation-ltd

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Mixed, from the last 12 quarters
- Price: ₹336.30 (−45.7% in a year)
- P/E: 16.1× (lower than 58% of the last 11 years)
- Revenue (Sep 2026): ₹413 Cr (+8.4% on a year ago)
- Profit (Sep 2026): ₹54.0 Cr (+10.2% on a year ago)
- Operating margin: 19.0% (flat on a year ago)
- ROCE: 36%, FY26
- ROIC: 34.2%, against a 12.0% cost of capital: +22.2 points

The main question: yearly earnings per share moved +14.1% while the share price moved −45.7%. ## What is the Indraprastha Medical Corporation share price today? Indraprastha Medical Corporation Ltd's share price was ₹336.30 at the close on 4 November 2026. It has been falling for 41 weeks. That is 11.6% below its average price over the last 200 trading days. In the last 52 weeks it traded between ₹300 and ₹620, and at that close it sat 11% of the way up from that low. Over the past 13 weeks it has done worse than the NIFTY 500, and it has been behind for 16 weeks running. Over the last 11 years the share price moved +573% while the NIFTY 500 moved +251%, so it is ahead of the index over that whole period. It was last ahead over 13 weeks in the week of 17 July 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at Indraprastha Medical Corporation this quarter? Three changes stood out: revenue up on a year earlier for 12 quarters in a row (every quarter we can compare), profit up on a year earlier for 12 quarters in a row (every quarter we can compare) and highest quarterly revenue in 16 quarters. 1. Revenue up on a year earlier for 12 quarters in a row (every quarter we can compare) In the September 2026 quarter revenue was ₹413 crore, +8.4% on a year earlier. 2. Profit up on a year earlier for 12 quarters in a row (every quarter we can compare) In the September 2026 quarter profit was ₹54 crore, +10.2% on a year earlier. 3. Highest quarterly revenue in 16 quarters Revenue of ₹413 crore in the September 2026 quarter is the highest of the last 16 quarters. ## What are Indraprastha Medical Corporation's latest quarterly results? For July to September 2026 (the quarter ended 30 September 2026), Indraprastha Medical Corporation reported revenue of ₹413 crore, up 8.4% from ₹381 crore a year earlier, and a profit of ₹54.0 crore, up 10.2% from ₹49.0 crore. ### Indraprastha Medical Corporation results: July to September 2026 against a year earlier

| Measure | July to September 2026 | July to September 2025 | Change |
| --- | --- | --- | --- |
| Revenue | ₹413 crore | ₹381 crore | +8.4% |
| Profit | ₹54.0 crore | ₹49.0 crore | +10.2% |
| Earnings per share | ₹5.84 | ₹5.40 | +8.1% |
| Operating margin | 19.0% | 19.0% | 0.0 points |

The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). (From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.)

## What is the Indraprastha Medical Corporation share price history? Indraprastha Medical Corporation closed at ₹336.30 on 4 November 2026, down 45.7% from ₹619.90 a year earlier (7 November 2025) and up 351.4% over five years. Its highest weekly close since March 2016 was ₹619.90 on 7 November 2025. ### Indraprastha Medical Corporation share price: then and now

| When | Close | Change to 4 Nov 2026 |
| --- | --- | --- |
| 1 week ago · 30 Oct 2026 | ₹305.65 | +10.0% |
| 1 month ago · 1 Oct 2026 | ₹338.60 | −0.7% |
| 6 months ago · 8 May 2026 | ₹425.30 | −20.9% |
| 1 year ago · 7 Nov 2025 | ₹619.90 | −45.7% |
| 3 years ago · 3 Nov 2023 | ₹169.90 | +97.9% |
| 5 years ago · 4 Nov 2021 | ₹74.50 | +351.4% |
| 10 years ago · 4 Nov 2016 | ₹55.70 | +503.8% |
| Earliest weekly close in our records · 11 Mar 2016 | ₹50.00 | +572.6% |
| Highest weekly close since March 2016, also the 52-week high · 7 Nov 2025 | ₹619.90 | −45.7% |
| Lowest weekly close since March 2016 · 27 Mar 2020 | ₹32.60 | +931.6% |
| 52-week low (weekly close) · 23 Oct 2026 | ₹299.80 | +12.2% |

Weekly closing prices. Each change is the move from that price to the 4 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (560 weekly closes from 11 March 2016 to 4 November 2026.)

## What is the latest news on Indraprastha Medical Corporation? 4 Nov 2026: Indraprastha Medical Corporation closed at ₹336.30, up 10.0% on the week and down 0.7% on the month. Results for July to September 2026: Revenue up 8.4% and profit up 10.2% on a year earlier. ### Earlier

- 18 Sep 2026: ex-date for a dividend of ₹4 a share. ## What dividend does Indraprastha Medical Corporation pay? Indraprastha Medical Corporation paid ₹4 a share in regular dividends in the 12 months to 5 November 2026 (1 payment), a yield of 1.19% at the ₹336.30 close on 4 November 2026. The last was a dividend of ₹4 a share, ex-date 18 September 2026. ### Indraprastha Medical Corporation dividends since 1 April 2021

| Ex-date | Dividend per share | Type |
| --- | --- | --- |
| 18 Sep 2026 | ₹4 | Dividend |
| 18 Sep 2025 | ₹4.50 | Dividend |
| 13 Sep 2024 | ₹4.50 | Dividend |
| 15 Sep 2023 | ₹3 | Dividend |
| 15 Sep 2022 | ₹2.50 | Dividend |

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. The record date is the same day as the ex-date for every payment here. 4 of 5 Of the last 5 financial years, years with an NSE dividend record

Yes. Indraprastha Medical Corporation Ltd paid out 20% of its profit as dividends in FY26, and it paid a dividend in 11 of its last 13 reported years. (From the NSE corporate-actions record, read 5 November 2026.)

## Which stock lists is Indraprastha Medical Corporation on? Indraprastha Medical Corporation is on one of our India lists: 52 week high & low. [52 week high & low 52-week position: Near 52-week low](https://www.sectoralpha.in/52-week-high-stocks-india)

## Is Indraprastha Medical Corporation profitable? Indraprastha Medical Corporation Ltd earned ₹54.0 Cr of net profit in the Sep 2026 quarter, +10.2% on the same quarter a year earlier. That is the 12th quarter in a row of profit growth. Full-year FY26 profit was ₹184 Cr. Over 10 years profit has grown 22.6% a year on average. That is 13.1% of the quarter's revenue. The same quarter a year earlier earned ₹49.0 Cr. For the full year, FY26 profit was ₹184 Cr (+14.3% on the year before). Why profit moved: revenue changed +8.4% on a year earlier and the margin moved +0.0 percentage points. Sales did the work, and the margin was about flat. On average over the last four quarters, profit changed +11.6% and revenue +10.8%. Profit and revenue are moving at about the same pace. ## How much revenue does Indraprastha Medical Corporation make, and is it growing? Indraprastha Medical Corporation Ltd reported ₹413 Cr of revenue in the Sep 2026 quarter, +8.4% on the same quarter a year earlier. That is the 12th quarter in a row with growth on the year before. Over 10 years it has grown 7.0% a year on average. The last full year, FY26, came in at ₹1,483 Cr. The last four reported quarters add to ₹1,556 Cr. FY26 revenue was ₹1,483 Cr, +9.4% on the year before. Recent pace: the last four quarters grew +10.8% on average, against 7.0% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +10.7%, against +8.6% a year over the last 8 quarters (stabilising); profit over the last 12 months grew +10.9%, against +14.6% a year (rolling over). ## How much of every ₹100 of sales does Indraprastha Medical Corporation keep? Indraprastha Medical Corporation Ltd's operating margin was 19.0% in the Sep 2026 quarter, about the same as the same quarter a year ago. Its latest full-year margin is the highest it has ever reported. Across 13 years it has been between 7.0% and 18.0%. The latest quarter is above every full year in that period. In the latest quarter it moved +0.0 percentage points on the same quarter a year ago. Why the margin moved: operating margin changed +0.0 percentage points on the year while gross margin changed +0.9 points. So the gain came mostly from the gross margin, which means input costs and prices charged. As noted under valuation: when margins are at a record, every ratio built on profit looks better than usual, so a low multiple can mislead. ## Is Indraprastha Medical Corporation's profit turning into cash? Over the last 3 years, 112% of Indraprastha Medical Corporation Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹167 Cr of operating cash against ₹184 Cr of profit. After ₹51.0 Cr of spending on assets, ₹116 Cr was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why 112% of profit came in as cash: the cash cycle got 12 days shorter between FY21 and FY26, so cash that used to wait in the business now arrives sooner. What to look at next: the bigger use of cash is spending on new assets, at 1.7× depreciation over three years. The next section checks what that spending is building. ## Where does Indraprastha Medical Corporation's cash go? Indraprastha Medical Corporation Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 28 days in FY26, down from 40 days in FY21. It spent ₹218 Cr on assets over the last 3 years. Customers take 28 days to pay, and stock sits for 11 days on average. At FY26 sales of ₹1,483 Cr, each day of that cycle ties up about ₹4.1 Cr, so roughly ₹114 Cr is tied up in the business at any time. FY26: customers took 28 days to pay and stock sat for 11 days, about 0.4 months of sales sitting as stock, for a full cycle of 28 days, shorter than FY21's 40. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 11 days. Customers pay about 28 days after that. Suppliers are paid at 182 days. Together that makes the 28-day cycle. Spending on assets: ₹218 Cr over the last 3 years, against ₹128 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹3.0 Cr (FY26): assets paid for that are not earning yet. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Indraprastha Medical Corporation's P/E ratio, and how does it compare with its own history? Indraprastha Medical Corporation Ltd's P/E is 16.1×, in the middle of its own history: higher than 42% of past readings. Its usual P/E (the middle reading) is 18.2×, over 11 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. Keep one thing in mind: margins are the best this company has ever reported. A multiple that looks low against its own past can mislead when profit is at a record. If margins fall back, today's multiple is higher than it looks. Why the multiple is where it is: over the past year earnings per share moved +14.1% while the price moved −45.7%. Earnings did better than the price, which pulled the multiple down within its own range. Where the price move came from: over 5 years the price moved +35.2% a year; about +34.9% a year came from earnings growth and about +0.3 percentage points from the multiple (roughly no change); over 10 years the price moved +19.7% a year; about +23.6% a year came from earnings growth and about −3.9 percentage points from the multiple (the market paying less). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is about average against its own past, so the earnings trend underneath matters more than the multiple. ## Is the Indraprastha Medical Corporation business getting better or worse? Indraprastha Medical Corporation Ltd's business is giving mixed signals. There is no clear direction across the growth lines, with ROCE falling at 32.5%; each line tells part of the story. This is based on 12 quarters of 4 measures. Why it matters: when the lines disagree, each line above matters more than any single label. ## How much does Indraprastha Medical Corporation earn on its capital? Indraprastha Medical Corporation Ltd earned a ROCE of 36% in FY26. That is up from a low of 3% in FY21. Its return on capital used (ROIC) is 22.2 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 12.4% net margin and 1.50× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 12.4% net margin × 1.50× asset turnover × 1.34× leverage (assets divided by equity) ≈ 24.9% on equity. The margin does its share; borrowing plays a small part, so this return is earned, not borrowed. The key test, return on capital used minus the cost of capital: 34.2% − 12.0% = +22.2 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. A gap this wide means each rupee put back into the business creates more than a rupee of value. The 34.2% ROIC above is the latest reading, as reported. The yearly chart below shows FY26 at 40.3%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does Indraprastha Medical Corporation have too much debt? Indraprastha Medical Corporation Ltd has total debt of ₹35.0 Cr against shareholder equity of ₹814 Cr as of Sep 2026, so its debt is 0.04× its equity, which is very little. Year by year, that ratio went from 0.02 in FY22 to 0.05 in FY26. So the returns on this page come from the business, not from borrowed money. ## What is the Indraprastha Medical Corporation shareholding pattern? Domestic institutions cut their stake in Indraprastha Medical Corporation Ltd by 1.4 percentage points over 8 quarters, the biggest change among its owners. Domestic institutions now own 1.8% of the company. Foreign institutions moved −0.3 points over the same period, to 2.4%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Over the last two years: Domestic institutions: −1.4 points over 8 quarters, to 1.8%; Foreign institutions: −0.3 points over 8 quarters, to 2.4%; Promoters: +0.0 points over 8 quarters, to 51.0%. Why the owners changed: domestic institutions drove it (−1.4 points). They reduced their stake. ## How far is Indraprastha Medical Corporation from balance-sheet trouble? For Indraprastha Medical Corporation Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Indraprastha Medical Corporation rank in its industry? 51.8 out of 100, rank 10 of 20 in Hospitals, with 85% of the evidence available. Indraprastha Medical Corporation Ltd scores 51.8 out of 100 against the 20 companies it is compared with in Hospitals, ranking 10. The valuation scores well, but earnings are not improving yet, so the business does not back up the low multiple so far. The four parts add up to the total exactly: 13.3 + 17.6 + 13.2 + 7.7 = 51.8. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Indraprastha Medical Corporation compared with? Indraprastha Medical Corporation ranks 10 of 20 Hospitals companies on the 4-Factor Sector Score, with 51.8 out of 100. 1. [KMC Speciality Hospitals (India) Ltd](https://www.sectoralpha.in/stocks/kmc-speciality-hospitals-indialtd) KMCSHIL · breaking out · Sector-leading setup · 81% evidence 80.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 31.0/35 · Revenue 35.1% · Profit 100% · Operating margin change 6 points · 88% evidence Capital efficiency 23.0/25 · ROCE 26.2% · Operating margin 31% · 100% evidence Valuation 14.1/20 · P/E 43.4× · PEG 0.68 · 100% evidence Relative strength 12.5/20 · Lead over its industry n/a · Lead over NIFTY 500 45.6% · 1 year 115.4% · 25% evidence · 5 of 5 weeks ahead Exact sum: 31 + 23 + 14.1 + 12.5 = 80.6 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 2. [Sakar Healthcare Ltd](https://www.sectoralpha.in/stocks/sakar-healthcare-ltd) SAKAR · leader · Most evidence points up · 100% evidence 68.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 32.5/35 · Revenue 47.5% · Profit 100% · Operating margin change 8 points · 100% evidence Capital efficiency 11.4/25 · ROCE 12.4% · Operating margin 28% · 100% evidence Valuation 11.1/20 · P/E 49× · PEG 1.05 · 100% evidence Relative strength 13.8/20 · Lead over its industry 41.8% · Lead over NIFTY 500 45.4% · 1 year 161.6% · 100% evidence · 12 of 12 weeks ahead Exact sum: 32.5 + 11.4 + 11.1 + 13.8 = 68.8 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 3. [Apollo Hospitals Enterprise Ltd](https://www.sectoralpha.in/stocks/apollo-hospitals-enterprise-ltd) APOLLOHOSP · turning · Most evidence points up · 78% evidence 68.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.0/35 · Revenue 17.2% · Profit 33.2% · Operating margin change 1 points · 83% evidence Capital efficiency 15.2/25 · ROCE 17.4% · Operating margin 16% · 76% evidence Valuation 12.7/20 · P/E 57.7× · PEG n/a · 50% evidence Relative strength 16.6/20 · Lead over its industry 6.6% · Lead over NIFTY 500 11.2% · 1 year 10% · 100% evidence · 4 of 12 weeks ahead Exact sum: 24 + 15.2 + 12.7 + 16.6 = 68.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 4. [Dr Agarwals Eye Hospital Ltd](https://www.sectoralpha.in/stocks/dr-agarwals-eye-hospital-ltd) DRAGARWQ · breaking out · Evidence leans up · 81% evidence 62.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.1/35 · Revenue 20.1% · Profit 31.6% · Operating margin change -2 points · 88% evidence Capital efficiency 17.3/25 · ROCE 17.2% · Operating margin 30% · 100% evidence Valuation 12.5/20 · P/E 33.7× · PEG 1.36 · 100% evidence Relative strength 11.6/20 · Lead over its industry n/a · Lead over NIFTY 500 9.2% · 1 year 0.8% · 25% evidence · 8 of 12 weeks ahead Exact sum: 21.1 + 17.3 + 12.5 + 11.6 = 62.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. [Kovai Medical Center & Hospital Ltd](https://www.sectoralpha.in/stocks/kovai-medical-center-hospital-ltd) KOVAI · breaking out · Evidence leans up · 96% evidence 61.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 18.8/35 · Revenue 15% · Profit 15.8% · Operating margin change 1 points · 88% evidence Capital efficiency 19.1/25 · ROCE 22.6% · Operating margin 29% · 100% evidence Valuation 8.9/20 · P/E 24.8× · PEG 2.01 · 100% evidence Relative strength 14.7/20 · Lead over its industry 1.9% · Lead over NIFTY 500 6.6% · 1 year -9.2% · 100% evidence · 10 of 12 weeks ahead Exact sum: 18.8 + 19.1 + 8.9 + 14.7 = 61.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [GPT Healthcare Ltd](https://www.sectoralpha.in/stocks/gpt-healthcare-ltd) GPTHEALTH · quiet · Evidence leans up · 81% evidence 61.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 15.4/35 · Revenue 18% · Profit 0% · Operating margin change 3 points · 88% evidence Capital efficiency 18.1/25 · ROCE 19.9% · Operating margin 19% · 100% evidence Valuation 18.5/20 · P/E 23× · PEG 0.94 · 100% evidence Relative strength 9.1/20 · Lead over its industry n/a · Lead over NIFTY 500 -2.1% · 1 year -10.7% · 25% evidence · 4 of 12 weeks ahead Exact sum: 15.4 + 18.1 + 18.5 + 9.1 = 61.1 · What this means: The valuation scores well, but earnings are not improving yet, so the business does not back up the low multiple so far. 7. [Yatharth Hospital & Trauma Care Services Ltd](https://www.sectoralpha.in/stocks/yatharth-hospital-trauma-care-services-ltd) YATHARTH · breaking out · Evidence leans up · 78% evidence 57.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.4/35 · Revenue 43.9% · Profit 22.5% · Operating margin change -2 points · 83% evidence Capital efficiency 12.4/25 · ROCE 12.9% · Operating margin 23% · 76% evidence Valuation 6.7/20 · P/E 49.3× · PEG n/a · 50% evidence Relative strength 19.1/20 · Lead over its industry 17.1% · Lead over NIFTY 500 21.6% · 1 year 16.4% · 100% evidence · 10 of 12 weeks ahead Exact sum: 19.4 + 12.4 + 6.7 + 19.1 = 57.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [Artemis Medicare Services Ltd](https://www.sectoralpha.in/stocks/artemis-medicare-services-ltd) ARTEMISMED · leader · Evidence leans up · 100% evidence 56.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.4/35 · Revenue 14.7% · Profit 20% · Operating margin change 0 points · 100% evidence Capital efficiency 12.7/25 · ROCE 14.6% · Operating margin 18% · 100% evidence Valuation 8.0/20 · P/E 39.7× · PEG 2.44 · 100% evidence Relative strength 16.7/20 · Lead over its industry 8.4% · Lead over NIFTY 500 12.9% · 1 year 18.4% · 100% evidence · 12 of 12 weeks ahead Exact sum: 19.4 + 12.7 + 8 + 16.7 = 56.8 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 9. [Global Health Ltd](https://www.sectoralpha.in/stocks/global-health-ltd) MEDANTA · losing its lead · Evidence leans up · 96% evidence 52.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 13.5/35 · Revenue 21.3% · Profit 3.4% · Operating margin change -2 points · 88% evidence Capital efficiency 18.8/25 · ROCE 17.4% · Operating margin 22% · 100% evidence Valuation 5.5/20 · P/E 59.7× · PEG 9.11 · 100% evidence Relative strength 14.2/20 · Lead over its industry 3.7% · Lead over NIFTY 500 8.1% · 1 year -3.1% · 100% evidence · 8 of 12 weeks ahead Exact sum: 13.5 + 18.8 + 5.5 + 14.2 = 52 · What this means: Relative strength against the index is 8.1%, and revenue and profit growth are weak. 10. Indraprastha Medical Corporation Ltd this page INDRAMEDCO · quiet · Evidence leans up · 85% evidence 51.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 13.3/35 · Revenue 10.8% · Profit 10.9% · Operating margin change 0 points · 100% evidence Capital efficiency 17.6/25 · ROCE 35.8% · Operating margin 19% · 100% evidence Valuation 13.2/20 · P/E 14.6× · PEG 1.47 · 100% evidence Relative strength 7.7/20 · Lead over its industry n/a · Lead over NIFTY 500 -19.7% · 1 year -49.6% · 25% evidence · 0 of 12 weeks ahead Exact sum: 13.3 + 17.6 + 13.2 + 7.7 = 51.8 · What this means: The valuation scores well, but earnings are not improving yet, so the business does not back up the low multiple so far. 11. [Rainbow Childrens Medicare Ltd](https://www.sectoralpha.in/stocks/rainbow-childrens-medicare-ltd) RAINBOW · quiet · Evidence leans up · 100% evidence 50.1 out of 100 Growth Capital Valuation Relative
12. [Max Healthcare Institute Ltd](https://www.sectoralpha.in/stocks/max-healthcare-institute-ltd) MAXHEALTH · quiet · Evidence leans down · 85% evidence 48.5 out of 100 Growth Capital Valuation Relative
13. [Fortis Healthcare Ltd](https://www.sectoralpha.in/stocks/fortis-healthcare-ltd) FORTIS · basing · Evidence leans down · 78% evidence 45.1 out of 100 Growth Capital Valuation Relative
14. [Shalby Ltd](https://www.sectoralpha.in/stocks/shalby-ltd) SHALBY · quiet · Evidence leans down · 63% evidence 42.0 out of 100 Growth Capital Valuation Relative
15. [Narayana Hrudayalaya Ltd](https://www.sectoralpha.in/stocks/narayana-hrudayalaya-ltd) NH · quiet · Evidence leans down · 78% evidence 40.7 out of 100 Growth Capital Valuation Relative
16. [Aster DM Quality Care Ltd](https://www.sectoralpha.in/stocks/aster-dm-quality-care-ltd) ASTERDM · quiet · Evidence leans down · 96% evidence 35.0 out of 100 Growth Capital Valuation Relative
17. [Krishna Institute of Medical Sciences Ltd](https://www.sectoralpha.in/stocks/krishna-institute-of-medical-sciences-ltd) KIMS · quiet · Most evidence points down · 78% evidence 34.8 out of 100 Growth Capital Valuation Relative
18. [Jupiter Life Line Hospitals Ltd](https://www.sectoralpha.in/stocks/jupiter-life-line-hospitals-ltd) JLHL · quiet · Most evidence points down · 100% evidence 33.0 out of 100 Growth Capital Valuation Relative
19. [Healthcare Global Enterprises Ltd](https://www.sectoralpha.in/stocks/healthcare-global-enterprises-ltd) HCG · quiet · Most evidence points down · 71% evidence 31.1 out of 100 Growth Capital Valuation Relative
20. [Manipal Health Enterprises Ltd](https://www.sectoralpha.in/stocks/manipal-health-enterprises-ltd) MANIPALHOS · Too little evidence to rank firmly · 38% evidence 42.4 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Hospitals](https://www.sectoralpha.in/sectors/hospitals), all 20 compared on one page. ## Which companies are close to Indraprastha Medical Corporation in size? Indraprastha Medical Corporation is the 15th largest of 20 Hospitals companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Jupiter Life Line Hospitals, Kovai Medical Center & Hospital and Artemis Medicare Services. Just below it: Dr Agarwals Eye Hospital, KMC Speciality Hospitals (India) and Sakar Healthcare. ### Hospitals companies close in size

1. [Jupiter Life Line Hospitals Ltd](https://www.sectoralpha.in/stocks/jupiter-life-line-hospitals-ltd) ₹8,430 crore
2. [Kovai Medical Center & Hospital Ltd](https://www.sectoralpha.in/stocks/kovai-medical-center-hospital-ltd) ₹6,363 crore
3. [Artemis Medicare Services Ltd](https://www.sectoralpha.in/stocks/artemis-medicare-services-ltd) ₹4,642 crore
4. Indraprastha Medical Corporation Ltd ₹2,802 crore
5. [Dr Agarwals Eye Hospital Ltd](https://www.sectoralpha.in/stocks/dr-agarwals-eye-hospital-ltd) ₹2,570 crore
6. [KMC Speciality Hospitals (India) Ltd](https://www.sectoralpha.in/stocks/kmc-speciality-hospitals-indialtd) ₹2,420 crore
7. [Sakar Healthcare Ltd](https://www.sectoralpha.in/stocks/sakar-healthcare-ltd) ₹2,102 crore

[All 20 Hospitals companies, largest first](https://www.sectoralpha.in/sectors/hospitals#all-companies)

### Companies close in size in other industries

1. [Polyplex Corporation Ltd](https://www.sectoralpha.in/stocks/polyplex-corporation-ltd) ₹2,814 crore · Packaging - BOPP
2. [CIAN Agro Industries & Infrastructure Ltd](https://www.sectoralpha.in/stocks/cian-agro-industries-infrastructure-ltd) ₹2,812 crore · Edible Oils, Agro Processing
3. Indraprastha Medical Corporation Ltd ₹2,802 crore
4. [HLE Glascoat Ltd](https://www.sectoralpha.in/stocks/hle-glascoat-ltd) ₹2,800 crore · Glass - Others
5. [Monolithisch India Ltd](https://www.sectoralpha.in/stocks/monolithisch-india-ltd) ₹2,796 crore · Refractories

## What else do people ask about Indraprastha Medical Corporation? ### What is Indraprastha Medical Corporation's share price today? Indraprastha Medical Corporation Ltd's share price is ₹336.30, −45.7% over the past year. The whole company is worth ₹3,079 Cr on the market. In the last 52 weeks it traded between ₹300 to ₹620; today it is 11% of the way up from the low, 11.6% below its 200-day average (as of 4 November 2026). ### What were Indraprastha Medical Corporation's latest quarterly results? Indraprastha Medical Corporation Ltd reported revenue of ₹413 Cr and net profit of ₹54.0 Cr for the Sep 2026 quarter. Revenue rose 8.4% and profit rose 10.2% compared with a year earlier. Earnings per share were ₹5.84. The operating margin was 19.0%, 0.0 percentage points higher than a year earlier (as of 4 November 2026). ### What is Indraprastha Medical Corporation's market cap? Indraprastha Medical Corporation Ltd's market capitalisation is ₹3,079 Cr at a share price of ₹336.30. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 4 November 2026). ### How is Indraprastha Medical Corporation performing? Indraprastha Medical Corporation Ltd's share price has been falling for 41 weeks. In its latest quarter, revenue rose 8.4% and profit rose 10.2% compared with a year earlier. Over the past 13 weeks it has done worse than the NIFTY 500, for 16 weeks running (as of 4 November 2026). ### Will Indraprastha Medical Corporation's share price go up? This page does not forecast Indraprastha Medical Corporation Ltd's share price. What it shows instead: the share price is ₹336.30, and it has been falling for 41 weeks. Its P/E of 16.1× is higher than 42% of its own last 11 years (as of 4 November 2026). ### Who owns Indraprastha Medical Corporation? Promoters own 51.0% of Indraprastha Medical Corporation Ltd, foreign institutions 2.4%, domestic institutions 1.8% and the public 44.8% (latest quarter). The biggest change over the last two years: Domestic institutions cut their stake by 1.4 percentage points over 8 quarters (as of 4 November 2026). ### Does Indraprastha Medical Corporation have too much debt? No, Indraprastha Medical Corporation Ltd has little debt: its debt is 0.05× its equity, and its operating profit is 45 times its interest bill. FY26 borrowings were ₹37.0 Cr against equity of ₹741 Cr. So the returns on this page come from the business, not borrowed money (as of 4 November 2026). ### Where is Indraprastha Medical Corporation in its business cycle? Indraprastha Medical Corporation Ltd's FY26 operating margin was 18.0%, against a 13-year range of 7.0% to 18.0%: the top of its range, a record year. When profit is at a record, every ratio looks better than usual, and the story depends on margins staying high. The latest quarter was 19.0%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 4 November 2026). ### What could break the Indraprastha Medical Corporation story? The main question: yearly earnings per share moved +14.1% while the share price moved −45.7%. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 4 November 2026). ### Is Indraprastha Medical Corporation a stock worth studying right now? What the numbers show: Indraprastha Medical Corporation Ltd's earnings have grown faster than its share price. Earnings per share grew +14.1% in a year while the price moved −45.7%. The main open question: whether the price catches up with earnings that have already grown. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 4 November 2026). ## Lists

- 52 week high & low: https://www.sectoralpha.in/52-week-high-stocks-india

This is research, not advice. We’re not SEBI-registered.